Recce Pharmaceuticals (ASX:RCE) secured clearance from an independent non-data safety review board to continue a phase 2 clinical trial evaluating the Recce 327 topical gel as a potential antibacterial product for acute skin infections, including diabetic foot infections, according to a Monday filing with the Australian bourse.
The disclosure follows a safety and efficacy review in which no serious adverse events were noted, the filing said.
Company shares fell almost 5% at market close on Monday.
Price (AUD): $0.48, Change: $-0.025, Percent Change: -4.95%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.